Creutzfeldt–Jakob disease explained

Creutzfeldt–Jakob disease
Synonyms:Classic Creutzfeldt–Jakob disease, subacute spongiform encephalopathy, neurocognitive disorder due to prion disease, (historical) spastic pseudosclerosis
Field:Neurology
Pronounce:,
Complications:Aspiration pneumonia due to difficulty coughing and swallowing
Onset:Around 60
Duration:70% die within a year of diagnosis
Types:Sporadic (mutation), Familial (heredity), Iatrogenic (acquired), Variant (infection)
Causes:Prion
Risks:Having at least one living or deceased ancestor with the disease (in case of familial CJD)
Diagnosis:Based on symptoms and medical tests after other possible causes are ruled out
Differential:Encephalitis, chronic meningitis, Huntington's disease, Alzheimer's disease, Sjögren's syndrome[1]
Prevention:Gene editing of children at risk (for fCJD)
Treatment:None, only supportive care as this condition is untreatable
Medication:Various experimental treatments, For pain relief: Morphine, Methadone
Prognosis:Life expectancy greatly shortened, varies from 3 months to multiple years
Frequency:1 per million per year
Deaths:131 in the United Kingdom (2020) [2]

Creutzfeldt–Jakob disease (CJD), also known as subacute spongiform encephalopathy or neurocognitive disorder due to prion disease, is a fatal neurodegenerative disease.[3] Early symptoms include memory problems, behavioral changes, poor coordination, and visual disturbances. Later symptoms include dementia, involuntary movements, blindness, weakness, and coma. About 70% of people die within a year of diagnosis. The name "Creutzfeldt–Jakob disease" was introduced by Walther Spielmeyer in 1922, after the German neurologists Hans Gerhard Creutzfeldt and Alfons Maria Jakob.[4]

CJD is caused by abnormal folding of a protein known as a prion.[5] Infectious prions are misfolded proteins that can cause normally folded proteins to also become misfolded. About 85% of cases of CJD occur for unknown reasons, while about 7.5% of cases are inherited in an autosomal dominant manner.[6] Exposure to brain or spinal tissue from an infected person may also result in spread. There is no evidence that sporadic CJD can spread among people via normal contact or blood transfusions, although this is possible in variant Creutzfeldt–Jakob disease.[7] [8] Diagnosis involves ruling out other potential causes. An electroencephalogram, spinal tap, or magnetic resonance imaging may support the diagnosis.

There is no specific treatment for CJD.[9] Opioids may be used to help with pain, while clonazepam or sodium valproate may help with involuntary movements. CJD affects about one person per million people per year. Onset is typically around 60 years of age. The condition was first described in 1920. It is classified as a type of transmissible spongiform encephalopathy.[10] Inherited CJD accounts for about 10% of prion disease cases. Sporadic CJD is different from bovine spongiform encephalopathy (mad cow disease) and variant Creutzfeldt–Jakob disease (vCJD).[11]

Signs and symptoms

The first symptom of CJD is usually rapidly progressive dementia, leading to memory loss, personality changes, and hallucinations. Myoclonus (jerky movements) typically occurs in 90% of cases, but may be absent at initial onset.[12] Other frequently occurring features include anxiety, depression, paranoia, obsessive-compulsive symptoms, and psychosis.[13] This is accompanied by physical problems such as speech impairment, balance and coordination dysfunction (ataxia), changes in gait, and rigid posture. In most people with CJD, these symptoms are accompanied by involuntary movements. The duration of the disease varies greatly, but sporadic (non-inherited) CJD can be fatal within months or even weeks.[14] Most affected people die six months after initial symptoms appear, often of pneumonia due to impaired coughing reflexes. About 15% of people with CJD survive for two or more years.[15]

The symptoms of CJD are caused by the progressive death of the brain's nerve cells, which are associated with the build-up of abnormal prion proteins forming in the brain. When brain tissue from a person with CJD is examined under a microscope, many tiny holes can be seen where the nerve cells have died. Parts of the brain may resemble a sponge where the prions were infecting the areas of the brain.[16]

Cause

CJD is a type of transmissible spongiform encephalopathy (TSE), which are caused by prions. Prions are misfolded proteins that occur in the neurons of the central nervous system (CNS). They are thought to affect signaling processes, damaging neurons and resulting in degeneration that causes the spongiform appearance in the affected brain.[17]

The CJD prion is dangerous because it promotes refolding of the cellular prion protein into the diseased state.[18] The number of misfolded protein molecules will increase exponentially and the process leads to a large quantity of insoluble protein in affected cells. This mass of misfolded proteins disrupts neuronal cell function and causes cell death. Mutations in the gene for the prion protein can cause a misfolding of the dominantly alpha helical regions into beta pleated sheets. This change in conformation disables the ability of the protein to undergo digestion. Once the prion is transmitted, the defective proteins invade the brain and induce other prion protein molecules to misfold in a self-sustaining feedback loop. These neurodegenerative diseases are commonly called prion diseases.[19]

Transmission

The defective protein can be transmitted by contaminated harvested human brain products, corneal grafts,[20] dural grafts,[21] or electrode[22] implants and human growth hormone.[23]

It can be familial (fCJD); or it may appear without clear risk factors (sporadic form: sCJD). In the familial form, a mutation has occurred in the gene for PrP, PRNP, in that family. All types of CJD are transmissible irrespective of how they occur in the person.[24]

It is thought that humans can contract the variant form of the disease by eating food from animals infected with bovine spongiform encephalopathy (BSE), the bovine form of TSE also known as mad cow disease. However, it can also cause sCJD in some cases.[25] [26]

Cannibalism has also been implicated as a transmission mechanism for abnormal prions, causing the disease known as kuru, once found primarily among women and children of the Fore people in Papua New Guinea, who previously engaged in funerary cannibalism.[27] While the men of the tribe ate the muscle tissue of the deceased, women and children consumed other parts, such as the brain, and were more likely than men to contract kuru from infected tissue.[28]

Prions, the infectious agent of CJD, may not be inactivated by means of routine surgical instrument sterilization procedures. The World Health Organization and the US Centers for Disease Control and Prevention recommend that instrumentation used in such cases be immediately destroyed after use; short of destruction, it is recommended that heat and chemical decontamination be used in combination to process instruments that come in contact with high-infectivity tissues. Thermal depolymerization also destroys prions in infected organic and inorganic matter, since the process chemically attacks protein at the molecular level, although more effective and practical methods involve destruction by combinations of detergents and enzymes similar to biological washing powders.[29]

Genetics

People can also develop CJD because they carry a mutation of the gene that codes for the prion protein (PRNP), located on chromosome 202p12-pter. This occurs in only 10–15% of all CJD cases. In sporadic cases, the misfolding of the prion protein is a process that is hypothesized to occur as a result of the effects of aging on cellular machinery, explaining why the disease often appears later in life. An EU study determined that "87% of cases were sporadic, 8% genetic, 5% iatrogenic and less than 1% variant."[30]

Diagnosis

Testing for CJD has historically been problematic, due to nonspecific nature of early symptoms and difficulty in safely obtaining brain tissue for confirmation. The diagnosis may initially be suspected in a person with rapidly progressing dementia, particularly when they are also found with the characteristic medical signs and symptoms such as involuntary muscle jerking,[31] difficulty with coordination/balance and walking, and visual disturbances. Further testing can support the diagnosis and may include:

In recent years, studies have shown that the tumour marker neuron-specific enolase (NSE) is often elevated in CJD cases; however, its diagnostic utility is seen primarily when combined with a test for the 14-3-3 protein.[39], screening tests to identify infected asymptomatic individuals, such as blood donors, are not yet available, though methods have been proposed and evaluated.[40]

Imaging

Imaging of the brain may be performed during medical evaluation, both to rule out other causes and to obtain supportive evidence for diagnosis. Imaging findings are variable in their appearance, and also variable in sensitivity and specificity.[41] While imaging plays a lesser role in diagnosis of CJD,[42] characteristic findings on brain MRI in some cases may precede onset of clinical manifestations.[43]

Brain MRI is the most useful imaging modality for changes related to CJD. Of the MRI sequences, diffuse-weighted imaging sequences are most sensitive.[44] Characteristic findings are as follows:

Brain FDG PET-CT tends to be markedly abnormal, and is increasingly used in the investigation of dementias.

Histopathology

Testing of tissue remains the most definitive way of confirming the diagnosis of CJD, although it must be recognized that even biopsy is not always conclusive.[49]

In one-third of people with sporadic CJD, deposits of "prion protein (scrapie)", PrPSc, can be found in the skeletal muscle and/or the spleen.[50] Diagnosis of vCJD can be supported by biopsy of the tonsils, which harbor significant amounts of PrPSc; however, biopsy of brain tissue is the definitive diagnostic test for all other forms of prion disease. Due to its invasiveness, biopsy will not be done if clinical suspicion is sufficiently high or low. A negative biopsy does not rule out CJD, since it may predominate in a specific part of the brain.[51]

The classic histologic appearance is spongiform change in the gray matter: the presence of many round vacuoles from one to 50 micrometers in the neuropil, in all six cortical layers in the cerebral cortex or with diffuse involvement of the cerebellar molecular layer.[52] These vacuoles appear glassy or eosinophilic and may coalesce. Neuronal loss and gliosis are also seen.[53] Plaques of amyloid-like material can be seen in the neocortex in some cases of CJD.[54]

However, extra-neuronal vacuolization can also be seen in other disease states. Diffuse cortical vacuolization occurs in Alzheimer's disease, and superficial cortical vacuolization occurs in ischemia and frontotemporal dementia. These vacuoles appear clear and punched-out. Larger vacuoles encircling neurons, vessels, and glia are a possible processing artifact.

Classification

Types of CJD include:[55]

Clinical and pathologic characteristics[59]
Characteristic Classic CJD Variant CJD
Median age at death 68 years 28 years
Median duration of illness 4–5 months13–14 months
Clinical signs and symptoms Dementia; early neurologic signsProminent psychiatric/behavioral symptoms; painful dysesthesias; delayed neurologic signs
Periodic sharp waves on electroencephalogramOften present Often absent
Signal hyperintensity in the caudate nucleus and putamen on diffusion-weighted and FLAIR MRIOften present Often absent
Pulvinar sign-bilateral high signal intensities on axial FLAIR MRI. Also posterior thalamic involvement on sagittal T2 sequences Not reportedPresent in >75% of cases
Immunohistochemical analysis of brain tissueVariable accumulation.Marked accumulation of protease-resistant prion protein
Presence of agent in lymphoid tissueNot readily detected Readily detected
Increased glycoform ratio on immunoblot analysis of protease-resistant prion proteinNot reportedMarked accumulation of protease-resistant prion protein
Presence of amyloid plaques in brain tissueMay be present May be present

Treatment

As of 2024, there is no cure or effective treatment for CJD. Some of the symptoms like twitching can be managed, but otherwise treatment is palliative care.[60] Psychiatric symptoms like anxiety and depression can be treated with sedatives and antidepressants. Myoclonic jerks can be handled with clonazepam or sodium valproate. Opiates can help in pain.[61] Seizures are very uncommon but can nevertheless be treated with antiepileptic drugs.[62]

Prognosis

Life expectancy is greatly reduced for people with Creutzfeldt-Jakob disease, with the average being less than 6 months. As of 1981, no one was known to have lived longer than 2.5 years after the onset of CJD symptoms.[63] In 2011, Jonathan Simms, a Northern Irish man who lived 10 years after his diagnosis, was reported to be one of the world's longest survivors of variant Creutzfeldt–Jakob disease (vCJD).[64]

Epidemiology

CDC monitors the occurrence of CJD in the United States through periodic reviews of national mortality data. According to the CDC:[65] [66]

Further information from the CDC:[67]

Although not fully understood, additional information suggests that CJD rates in African American and nonwhite groups are lower than in whites. While the mean onset is approximately 67 years of age, cases of sCJD have been reported as young as 17 years and over 80 years of age. Mental capabilities rapidly deteriorate and the average amount of time from onset of symptoms to death is 7 to 9 months.[68]

According to a 2020 systematic review on the international epidemiology of CJD:[69]

The intensity of CJD surveillance increases the number of reported cases, often in countries where CJD epidemics have occurred in the past and where surveillance resources are greatest. An increase in surveillance and reporting of CJD is most likely in response to BSE and vCJD. Possible factors contributing to an increase of CJD incidence are an aging population, population increase, clinician awareness, and more accurate diagnostic methods. Since CJD symptoms are similar to other neurological conditions, it is also possible that CJD is mistaken for stroke, acute nephropathy, general dementia, and hyperparathyroidism.

History

The disease was first described by German neurologist Hans Gerhard Creutzfeldt in 1920 and shortly afterward by Alfons Maria Jakob, giving it the name Creutzfeldt–Jakob disease. Some of the clinical findings described in their first papers do not match current criteria for Creutzfeldt–Jakob disease, and it has been speculated that at least two of the people in initial studies had a different ailment.[70] An early description of familial CJD stems from the German psychiatrist and neurologist Friedrich Meggendorfer (1880–1953).[71] [72] A study published in 1997 counted more than 100 cases worldwide of transmissible CJD and new cases continued to appear at the time.[73]

The first report of suspected iatrogenic CJD was published in 1974. Animal experiments showed that corneas of infected animals could transmit CJD, and the causative agent spreads along visual pathways. A second case of CJD associated with a corneal transplant was reported without details. In 1977, CJD transmission caused by silver electrodes previously used in the brain of a person with CJD was first reported. Transmission occurred despite the decontamination of the electrodes with ethanol and formaldehyde. Retrospective studies identified four other cases likely of similar cause. The rate of transmission from a single contaminated instrument is unknown, although it is not 100%. In some cases, the exposure occurred weeks after the instruments were used on a person with CJD. In the 1980s it was discovered that Lyodura, a dura mater transplant product, was shown to transmit CJD from the donor to the recipient. This led to the product being banned in Canada but it was used in other countries such as Japan until 1993.[74]

A review article published in 1979 indicated that 25 dura mater cases had occurred by that date in Australia, Canada, Germany, Italy, Japan, New Zealand, Spain, the United Kingdom, and the United States.

By 1985, a series of case reports in the United States showed that when injected, cadaver-extracted pituitary human growth hormone could transmit CJD to humans.

In 1992, it was recognized that human gonadotropin administered by injection could also transmit CJD from person to person.

Stanley B. Prusiner of the University of California, San Francisco (UCSF) was awarded the Nobel Prize in Physiology or Medicine in 1997 "for his discovery of Prions—a new biological principle of infection".[75]

Yale University neuropathologist Laura Manuelidis has challenged the prion protein (PrP) explanation for the disease. In January 2007, she and her colleagues reported that they had found a virus-like particle in naturally and experimentally infected animals. "The high infectivity of comparable, isolated virus-like particles that show no intrinsic PrP by antibody labeling, combined with their loss of infectivity when nucleic acid–protein complexes are disrupted, make it likely that these 25-nm particles are the causal TSE virions".[76]

Australia

Australia has documented 10 cases of healthcare-acquired CJD (iatrogenic or ICJD). Five of the deaths resulted after the patients, who were in treatment either for infertility or short stature, were treated using contaminated pituitary extract hormone but no new cases have been noted since 1991. The other five deaths occurred due to dura grafting procedures that were performed during brain surgery, in which the covering of the brain is repaired. There have been no other ICJD deaths documented in Australia due to transmission during healthcare procedures.[77]

New Zealand

A case was reported in 1989 in a 25-year-old man from New Zealand, who also received dura mater transplant. Five New Zealanders have been confirmed to have died of the sporadic form of Creutzfeldt–Jakob disease (CJD) in 2012.[78]

United States

In 1988, there was a confirmed death from CJD of a person from Manchester, New Hampshire. Massachusetts General Hospital believed the person acquired the disease from a surgical instrument at a podiatrist's office. In 2007, Michael Homer, former Vice President of Netscape, had been experiencing consistent memory problems which led to his diagnosis.[79] In September 2013, another person in Manchester was posthumously determined to have died of the disease. The person had undergone brain surgery at Catholic Medical Center three months before his death, and a surgical probe used in the procedure was subsequently reused in other operations. Public health officials identified thirteen people at three hospitals who may have been exposed to the disease through the contaminated probe, but said the risk of anyone's contracting CJD is "extremely low".[80] [81] [82] In January 2015, former speaker of the Utah House of Representatives Rebecca D. Lockhart died of the disease within a few weeks of diagnosis.[83] John Carroll, former editor of The Baltimore Sun and Los Angeles Times, died of CJD in Kentucky in June 2015, after having been diagnosed in January.[84] American actress Barbara Tarbuck (General Hospital, American Horror Story) died of the disease on December 26, 2016.[85] José Baselga, clinical oncologist having headed the AstraZeneca Oncology division, died in Cerdanya, March 21, 2021, from CJD.[86] In April 2024, two hunters from the same lodge were found to be afflicted with Sporadic CJD after eating deer meat infected with chronic wasting disease (CWD), suggesting a potential link between CWD and CJD.[87]

Research

Diagnosis

Treatment

See also

Notes and References

  1. Notas K, Papaliagkas V, Spilioti M, Papagiannis I, Nemtsas P, Poulopoulos A, Kouskouras K, Diakogiannis I, Kimiskidis VK. Primary Sjögren's Syndrome Presenting with Rapidly Progressive Dementia: A Case Report. Curr Alzheimer Res. 2022;19(6):479-484. doi: 10.2174/1567205019666220627094707. PMID 35761497.
  2. Web site: Creutzfeldt-Jakob disease . 23 October 2017 .
  3. Web site: Creutzfeldt-Jakob Disease, Classic (CJD) . CDC . 21 November 2018 . 2 October 2018.
  4. http://www.whonamedit.com/synd.cfm/696.html Creutzfeldt–Jakob disease
  5. Web site: Creutzfeldt-Jakob Disease, Classic (CJD) Prion Diseases CDC . www.cdc.gov . 17 June 2019 . en-us . 1 February 2019. Classic CJD is a human prion disease.
  6. Manix. Marc. Kalakoti. Piyush. Henry. Miriam. Thakur. Jai. Menger. Richard. Guthikonda. Bharat. Nanda. Anil. 2015-11-01. Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy. Neurosurgical Focus. en-US. 39. 5. E2. 10.3171/2015.8.FOCUS15328. 26646926. 1092-0684. free.
  7. Brandel J, Vlaciu M, Culeux A, Belondrade M, Grznarova K, Plu I, Levasseur M, Haik S . Variant Creutzfeldt–Jakob Disease Diagnosed 7.5 Years after Occupational Exposure . New England Journal of Medicine . 383 . July 2, 2020 . 1 . 83–85 . 10.1056/NEJMc2000687 . 32609989 . free.
  8. Web site: Transfusion Handbook/ 5.4: Variant Creutzfeldt–Jakob disease (vCJD). Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee. 29 July 2021. 4 February 2014. live. https://web.archive.org/web/20170305085007/http://transfusionguidelines.org/transfusion-handbook/5-adverse-effects-of-transfusion/5-4-variant-creutzfeldt-jakob-disease-vcjd . 2017-03-05.
  9. Web site: Creutzfeldt–Jakob Disease Fact Sheet National Institute of Neurological Disorders and Stroke. NINDS. 16 July 2017. March 2003. live. https://web.archive.org/web/20170704234755/https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Creutzfeldt-Jakob-Disease-Fact-Sheet. 4 July 2017.
  10. Web site: About CJD Creutzfeldt–Jakob Disease, Classic (CJD) Prion Disease. CDC. 16 July 2017. 11 February 2015. live. https://web.archive.org/web/20170808104028/https://www.cdc.gov/prions/cjd/about.html. 8 August 2017.
  11. Web site: Creutzfeldt–Jakob Disease, Classic (CJD) Prion Diseases. CDC. 16 July 2017. 6 February 2015. live. https://web.archive.org/web/20170718154357/https://www.cdc.gov/prions/cjd/index.html. 18 July 2017.
  12. Web site: A 49-Year-Old Man With Forgetfulness and Gait Impairment. https://web.archive.org/web/20170706181402/http://reference.medscape.com/viewarticle/881806_3. dead. 2017-07-06. reference.medscape.com/viewarticle/881806_3. 2017-07-09.
  13. Murray ED, Buttner N, Price BH. (2012) Depression and Psychosis in Neurological Practice. In: Neurology in Clinical Practice, 6th Edition. Bradley WG, Daroff RB, Fenichel GM, Jankovic J (eds.) Butterworth Heinemann. April 12, 2012.
  14. Brown P, Cathala F, Castaigne P, Gajdusek DC . Creutzfeldt-Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases . Annals of Neurology . 20 . 5 . 597–602 . November 1986 . 3539001 . 10.1002/ana.410200507 . 7995631.
  15. Web site: Gambetti. Pierluigi. Creutzfeldt–Jakob Disease (CJD). The Merck Manuals: Online Medical Library. 2011-06-04. live. https://web.archive.org/web/20110604015739/http://www.merckmanuals.com/home/sec06/ch090/ch090b.html. 2011-06-04.
  16. Atalay. Fatma Oz. Tolunay. Sahsine. Ozgun. Gonca. Bekar. Ahmet. Zarifoglu. Mehmet. 2013. Creutzfeldt-jakob disease: report of four cases and review of the literature. Turkish Journal of Pathology. 31. 2. 148–152. 10.5146/tjpath.2013.01195. 24272930. 1018-5615. free.
  17. Book: Sattar, Husain A. . Fundamentals of Pathology. 189. 978-0-9832246-3-1 . 2017 . Pathoma.com.
  18. Clarke AR, Jackson GS, Collinge J . The molecular biology of prion propagation . Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences . 356 . 1406 . 185–95 . February 2001 . 11260799 . 1088424 . 10.1098/rstb.2000.0764.
  19. Geschwind . MD . Prion Diseases . Continuum . 2015 . 21 . 6 . 1612–1638 . 10.1212/CON.0000000000000251 . 26633779 . 4879966.
  20. Armitage WJ, Tullo AB, Ironside JW . Risk of Creutzfeldt-Jakob disease transmission by ocular surgery and tissue transplantation . Eye . 23 . 10 . 1926–30 . October 2009 . 19136921 . 10.1038/eye.2008.381 . free.
  21. Esmonde T, Lueck CJ, Symon L, Duchen LW, Will RG . Creutzfeldt-Jakob disease and lyophilised dura mater grafts: report of two cases . Journal of Neurology, Neurosurgery, and Psychiatry . 56 . 9 . 999–1000 . September 1993 . 8410042 . 489736 . 10.1136/jnnp.56.9.999.
  22. Bernoulli C, Siegfried J, Baumgartner G, Regli F, Rabinowicz T, Gajdusek DC, Gibbs CJ . Franco Regli . Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery . Lancet . 1 . 8009 . 478–9 . February 1977 . 65575 . 10.1016/s0140-6736(77)91958-4 . 26804024.
  23. Brown P, Brandel JP, Sato T, Nakamura Y, MacKenzie J, Will RG, Ladogana A, Pocchiari M, Leschek EW, Schonberger LB . Iatrogenic Creutzfeldt-Jakob disease, final assessment . Emerging Infectious Diseases . 18 . 6 . 901–7 . June 2012 . 22607808 . 3358170 . 10.3201/eid1806.120116.
  24. Brown P, Gibbs CJ, Rodgers-Johnson P, Asher DM, Sulima MP, Bacote A, Goldfarb LG, Gajdusek DC . Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease . Annals of Neurology . 35 . 5 . 513–29 . May 1994 . 8179297 . 10.1002/ana.410350504 . 22496358.
  25. Web site: New form of BSE resembles sporadic CJD. CIDRAP. 19 February 2004.
  26. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF . 4355186 . Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD . Nature . 383 . 6602 . 685–90 . October 1996 . 8878476 . 10.1038/383685a0 . 1996Natur.383..685C.
  27. Collinge J, Whitfield J, McKintosh E, Beck J, Mead S, Thomas DJ, Alpers MP . Kuru in the 21st century--an acquired human prion disease with very long incubation periods . Lancet . 367 . 9528 . 2068–74 . June 2006 . 16798390 . 10.1016/s0140-6736(06)68930-7 . 11506094.
  28. Liberski . Pawel P. . 2013 . Kuru: A Journey Back in Time from Papua New Guinea to the Neanderthals' Extinction . Pathogens . en . 2 . 3 . 472–505 . 10.3390/pathogens2030472 . 25437203. 4235695 . free.
  29. Jackson GS, McKintosh E, Flechsig E, Prodromidou K, Hirsch P, Linehan J, Brandner S, Clarke AR, Weissmann C, Collinge J . An enzyme-detergent method for effective prion decontamination of surgical steel . The Journal of General Virology . 86 . Pt 3 . 869–78 . March 2005 . 15722550 . 10.1099/vir.0.80484-0 . free.
  30. Will RG, Alperovitch A, Poser S, Pocchiari M, Hofman A, Mitrova E, de Silva R, D'Alessandro M, Delasnerie-Laupretre N, Zerr I, van Duijn C . Descriptive epidemiology of Creutzfeldt-Jakob disease in six European countries, 1993-1995. EU Collaborative Study Group for CJD . Annals of Neurology . 43 . 6 . 763–7 . June 1998 . 9629846 . 10.1002/ana.410430611 . 13562215.
  31. Book: Sattar, Hussain A. . Fundamentals of Pathology. 2011. limited. Pathoma LLC.. Chicago . 187 . 978-0-9832246-0-0.
  32. Mead S, Rudge P . CJD mimics and chameleons . Practical Neurology . 17 . 2 . 113–121 . April 2017 . 28153848 . 5520355 . 10.1136/practneurol-2016-001571.
  33. Satoh J, Kurohara K, Yukitake M, Kuroda Y . 21795464 . The 14-3-3 protein detectable in the cerebrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture . European Neurology . 41 . 4 . 216–25 . 1999 . 10343153 . 10.1159/000008054.
  34. Geschwind MD, Martindale J, Miller D, DeArmond SJ, Uyehara-Lock J, Gaskin D, Kramer JH, Barbaro NM, Miller BL . Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease . Archives of Neurology . 60 . 6 . 813–6 . June 2003 . 12810484 . 10.1001/archneur.60.6.813 .
  35. Chitravas N, Jung RS, Kofskey DM, Blevins JE, Gambetti P, Leigh RJ, Cohen ML . Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease . Annals of Neurology . 70 . 3 . 437–44 . September 2011 . 21674591 . 3170496 . 10.1002/ana.22454.
  36. Sano K, Satoh K, Atarashi R, Takashima H, Iwasaki Y, Yoshida M, Sanjo N, Murai H, Mizusawa H, Schmitz M, Zerr I, Kim YS, Nishida N . Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QUIC assay . PLOS ONE . 8 . 1 . e54915 . 2013-01-25 . 23372790 . 3556051 . 10.1371/journal.pone.0054915 . 2013PLoSO...854915S . free.
  37. Foutz A, Appleby BS, Hamlin C, Liu X, Yang S, Cohen Y, Chen W, Blevins J, Fausett C, Wang H, Gambetti P, Zhang S, Hughson A, Tatsuoka C, Schonberger LB, Cohen ML, Caughey B, Safar JG . Diagnostic and prognostic value of human prion detection in cerebrospinal fluid . Annals of Neurology . 81 . 1 . 79–92 . January 2017 . 27893164 . 5266667 . 10.1002/ana.24833.
  38. Bongianni M, Orrù C, Groveman BR, Sacchetto L, Fiorini M, Tonoli G, Triva G, Capaldi S, Testi S, Ferrari S, Cagnin A, Ladogana A, Poleggi A, Colaizzo E, Tiple D, Vaianella L, Castriciano S, Marchioni D, Hughson AG, Imperiale D, Cattaruzza T, Fabrizi GM, Pocchiari M, Monaco S, Caughey B, Zanusso G . 40578363 . Diagnosis of Human Prion Disease Using Real-Time Quaking-Induced Conversion Testing of Olfactory Mucosa and Cerebrospinal Fluid Samples . JAMA Neurology . 74 . 2 . 155–162 . February 2017 . 27942718 . 10.1001/jamaneurol.2016.4614.
  39. Sanchez-Juan P, Green A, Ladogana A, Cuadrado-Corrales N, Sáanchez-Valle R, Mitrováa E, Stoeck K, Sklaviadis T, Kulczycki J, Hess K, Bodemer M, Slivarichová D, Saiz A, Calero M, Ingrosso L, Knight R, Janssens AC, van Duijn CM, Zerr I . 23306766 . CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease . Neurology . 67 . 4 . 637–43 . August 2006 . 16924018 . 10.1212/01.wnl.0000230159.67128.00.
  40. Tattum MH, Jones S, Pal S, Khalili-Shirazi A, Collinge J, Jackson GS . A highly sensitive immunoassay for the detection of prion-infected material in whole human blood without the use of proteinase K . Transfusion . 50 . 12 . 2619–27 . December 2010 . 20561299 . 10.1111/j.1537-2995.2010.02731.x . 33032755 . Submitted manuscript.
  41. Fragoso DC, Gonçalves Filho AL, Pacheco FT, Barros BR, Aguiar Littig I, Nunes RH, Maia Júnior AC, da Rocha AJ . Imaging of Creutzfeldt-Jakob Disease: Imaging Patterns and Their Differential Diagnosis . Radiographics . 37 . 1 . 234–257 . 2017-01-01 . 28076012 . 10.1148/rg.2017160075 .
  42. Finkenstaedt M, Szudra A, Zerr I, Poser S, Hise JH, Stoebner JM, Weber T . MR imaging of Creutzfeldt-Jakob disease . Radiology . 199 . 3 . 793–8 . June 1996 . 8638007 . 10.1148/radiology.199.3.8638007.
  43. Ukisu R, Kushihashi T, Kitanosono T, Fujisawa H, Takenaka H, Ohgiya Y, Gokan T, Munechika H . Serial diffusion-weighted MRI of Creutzfeldt-Jakob disease . AJR. American Journal of Roentgenology . 184 . 2 . 560–6 . February 2005 . 15671380 . 10.2214/ajr.184.2.01840560.
  44. Kumaran . Sunitha P. . Gupta . Kanchan . Pushpa . B. T. . Viswamitra . Sanjaya . Joshy . E. V. . 2012 . Diffusion-weighted imaging: As the first diagnostic clue to Creutzfeldt Jacob disease . Journal of Neurosciences in Rural Practice . en . 3 . 3 . 408–410 . 10.4103/0976-3147.102645 . 0976-3147 . 23189017. 3505356 . free.
  45. Young GS, Geschwind MD, Fischbein NJ, Martindale JL, Henry RG, Liu S, Lu Y, Wong S, Liu H, Miller BL, Dillon WP . Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis . AJNR. American Journal of Neuroradiology . 26 . 6 . 1551–62 . June–July 2005 . 15956529 . 8149066 . https://web.archive.org/web/20080907152111/http://www.ajnr.org/cgi/content/full/26/6/1551 . live . 2008-09-07.
  46. Abdulmassih R, Min Z . An ominous radiographic feature: cortical ribbon sign . Internal and Emergency Medicine . 11 . 2 . 281–3 . March 2016 . 26238299 . 10.1007/s11739-015-1287-4 . free.
  47. Tschampa HJ, Mürtz P, Flacke S, Paus S, Schild HH, Urbach H . Thalamic involvement in sporadic Creutzfeldt-Jakob disease: a diffusion-weighted MR imaging study . AJNR. American Journal of Neuroradiology . 24 . 5 . 908–15 . May 2003 . 12748093 . 7975779 . https://web.archive.org/web/20081010214648/http://www.ajnr.org/cgi/content/full/24/5/908 . live . 10 October 2008.
  48. Morley NC, Hofer M, Wilkinson P, Bradley KM . 18FDG PET-CT in sporadic Creutzfeldt-Jakob disease, correlated with MRI and histology . World J Nucl Med . 2021 . 20 . 4 . 411–413 . 10.4103/wjnm.wjnm_5_21 . 35018165 . 8686746 . 244465297 . free.
  49. Connor . Allyson . Wang . Han . Appleby . Brian S. . Rhoads . Daniel D. . 2019-09-24 . Clinical Laboratory Tests Used To Aid in Diagnosis of Human Prion Disease . Journal of Clinical Microbiology . 57 . 10 . e00769–19 . 10.1128/JCM.00769-19 . 0095-1137 . 6760952 . 31366689.
  50. Igel-Egalon . Angélique . Béringue . Vincent . Rezaei . Human . Sibille . Pierre . 2018 . Prion Strains and Transmission Barrier Phenomena . Pathogens . en . 7 . 1 . 5 . 10.3390/pathogens7010005 . 29301257 . 5874731 . 2076-0817. free.
  51. Sternberg's Diagnostic Surgical Pathology, 5th edition.
  52. Liberski, P.P.. 2004. Spongiform change – an electron microscopic view.. Folia Neuropathologica. 42, suppl B. 59–70. 16903142.
  53. Web site: Pathology of Degenerative CNS Diseases. library.med.utah.edu.
  54. G. B.. Dudhatra. Kumar. Avinash. C. M.. Modi. M. M.. Awale. H. B.. Patel. S. K.. Mody. 2012-08-14. Transmissible Spongiform Encephalopathies Affecting Humans. ISRN Infectious Diseases. 2013. 1–11. 10.5402/2013/387925. en. free.
  55. Budka H, Will RG . The end of the BSE saga: do we still need surveillance for human prion diseases? . Swiss Medical Weekly . 145 . w14212 . 12 November 2015 . 26715203 . 10.4414/smw.2015.14212 . free.
  56. Ridley RM, Baker HF, Crow TJ . Transmissible and non-transmissible neurodegenerative disease: similarities in age of onset and genetics in relation to aetiology . Psychological Medicine . 16 . 1 . 199–207 . February 1986 . 3961045 . 10.1017/s0033291700002634 . 38449324.
  57. Web site: who.int: "Fact sheets no 180: Variant Creutzfeldt–Jakob disease" Feb 2012 ed.. https://web.archive.org/web/20160204002108/http://www.who.int/mediacentre/factsheets/fs180/en/. dead. February 4, 2016.
  58. Bonda DJ, Manjila S, Mehndiratta P, Khan F, Miller BR, Onwuzulike K, Puoti G, Cohen ML, Schonberger LB, Cali I . Human prion diseases: surgical lessons learned from iatrogenic prion transmission . Neurosurgical Focus . 41 . 1 . E10 . July 2016 . 27364252 . 5082740 . 10.3171/2016.5.FOCUS15126.
  59. Belay ED, Schonberger LB . Variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy . Clinics in Laboratory Medicine . 22 . 4 . 849–62, v-vi . December 2002 . 12489284 . 10.1016/S0272-2712(02)00024-0.
  60. Manix M, Kalakoti P, Henry M, Thakur J, Menger R, Guthikonda B, Nanda A . Creutzfeldt-Jakob disease: updated diagnostic criteria, treatment algorithm, and the utility of brain biopsy . Neurosurgical Focus . 39 . 5 . E2 . November 2015 . 26646926 . 10.3171/2015.8.FOCUS15328 . free.
  61. Web site: Treatment. nhs.uk. 2018-04-17. 2017-10-23.
  62. Ng MC, Westover MB, Cole AJ . Treating seizures in Creutzfeldt-Jakob disease . Epilepsy & Behavior Case Reports . 2 . 75–9 . 2014-02-07 . 25667875 . 4308028 . 10.1016/j.ebcr.2014.01.004.
  63. Mizutani T, Okumura A, Oda M, Shiraki H . Panencephalopathic type of Creutzfeldt-Jakob disease: primary involvement of the cerebral white matter . Journal of Neurology, Neurosurgery, and Psychiatry . 44 . 2 . 103–15 . February 1981 . 7012278 . 490840 . 10.1136/jnnp.44.2.103.
  64. News: Belfast man with VCJD dies after long battle. BBC News. 7 March 2011.
  65. Web site: CJD (Creutzfeldt–Jakob Disease, Classic) . Centers for Disease Control and Prevention . 2008-02-26 . 2009-06-20 . dead . https://web.archive.org/web/20090506212244/http://www.cdc.gov/ncidod/dvrd/cjd/index.htm . 2009-05-06.
  66. Web site: vCJD (Variant Creutzfeldt–Jakob Disease) . Centers for Disease Control and Prevention . 2007-01-04 . 2009-06-20 . dead . https://web.archive.org/web/20090507193309/http://www.cdc.gov/ncidod/dvrd/vcjd/factsheet_nvcjd.htm . 2009-05-07.
  67. https://www.cdc.gov/prions/cjd/occurrence-transmission.html "Occurrence and Transmission | Creutzfeldt-Jakob Disease, Classic (CJD) | Prion Disease | CDC".
  68. Book: Bosque. Patrick. Prions and Prion Disease of the Central Nervous System (Transmissible Neurodegenerative Diseases). Tyler. Kenneth. Elsevier, Inc. 2020. www.clinicalkey.com. 2288–2300.
  69. Uttley . Lesley . Carroll . Christopher . Wong . Ruth . Hilton . David A. . Stevenson . Matt . January 2020 . Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation . The Lancet. Infectious Diseases . 20 . 1 . e2–e10 . 10.1016/S1473-3099(19)30615-2 . 31876504. 209483271 . https://ghostarchive.org/archive/20221009/http://eprints.whiterose.ac.uk/155256/9/CJD%20review_submitted%20to%20TLID%2013.09.19%20for%20WRR.pdf . 2022-10-09 . live.
  70. Book: Ironside JW . 1996 . Neuropathological diagnosis of human prion disease; morphological studies. Prion Diseases . Baker HF, Ridley RM . 3. 35–57 . 978-0-89603-342-9. 10.1385/0896033422.
  71. Meggendorfer F . 1930 . Klinische und genealogische Beobachtungen bei einem Fall von spastischer Pseudokosklerose Jakobs . Zeitschrift für die Gesamte Neurologie und Psychiatrie . 128 . 1–4. 337–41 . 10.1007/bf02864269. 178922541.
  72. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG . Sporadic and familial CJD: classification and characterisation . British Medical Bulletin . 66 . 213–39 . 2003 . 14522861 . 10.1093/bmb/66.1.213 . free.
  73. Ricketts MN, Cashman NR, Stratton EE, ElSaadany S . Is Creutzfeldt-Jakob disease transmitted in blood? . Emerging Infectious Diseases . 3 . 2 . 155–63 . 1997 . 9204296 . 2627622 . 10.3201/eid0302.970208.
  74. Ae R, Hamaguchi T, Nakamura Y, Yamada M, Tsukamoto T, Mizusawa H, Belay ED, Schonberger LB . Update: Dura Mater Graft-Associated Creutzfeldt-Jakob Disease - Japan, 1975-2017 . MMWR. Morbidity and Mortality Weekly Report . 67 . 9 . 274–278 . March 2018 . 29518068 . 5844283 . 10.15585/mmwr.mm6709a3.
  75. Web site: The Nobel Prize in Physiology or Medicine 1997: Stanley B. Prusiner . NobelPrize.org . 2011-02-21 . live . https://web.archive.org/web/20110220075157/http://nobelprize.org/nobel_prizes/medicine/laureates/1997/ . 2011-02-20.
  76. Manuelidis L, Yu ZX, Barquero N, Banquero N, Mullins B . Cells infected with scrapie and Creutzfeldt-Jakob disease agents produce intracellular 25-nm virus-like particles . Proceedings of the National Academy of Sciences of the United States of America . 104 . 6 . 1965–70 . February 2007 . 17267596 . 1794316 . 10.1073/pnas.0610999104 . 2007PNAS..104.1965M . free.
  77. http://ideas.health.vic.gov.au/diseases/cjd-facts.asp Creutzfeldt–Jakob Disease (CJD) – the facts.
  78. Web site: Mad cow link in hunter's death. Stuff. 16 November 2012.
  79. via Bloomberg News, "Mike Homer dies at 50; a former vice president of Netscape", Los Angeles Times, February 5, 2009. Accessed February 6, 2009.
  80. Web site: Autopsy confirms rare brain disease in NH patient. MyFoxBoston. 20 September 2013. live. https://web.archive.org/web/20130921055822/http://www.myfoxboston.com/story/23489308/2013/09/20/autopsy-confirms-rare-brain-disease-in-nh-patient. 21 September 2013. 2013-09-20.
  81. Web site: NH Patient Likely Died of Rare Brain Disease. AP. 5 September 2013. live. https://web.archive.org/web/20130908120727/http://bigstory.ap.org/article/surgical-gear-quarantined-over-rare-brain-disease. 8 September 2013.
  82. News: Kowalczyk . Liz . 5 patients at Cape hospital at risk for rare brain disease . Boston Globe . 25 November 2013 . dead . https://web.archive.org/web/20130909210818/http://www.boston.com/news/local/massachusetts/2013/09/05/cape-cod-hospital-patients-possibly-exposed-brain-disease/CwGauqzFxf6Om8agTvUoAJ/story.html . 9 September 2013.
  83. Web site: Officials: Lockhart, 'Utah's Iron Lady' died from Creutzfeldt-Jakob disease . 2015-01-18 . live . https://web.archive.org/web/20150120045509/http://www.heraldextra.com/news/local/central/provo/officials-lockhart-died-from-creutzfeldt-jakob-disease/article_ab2ba7d7-26b0-5e7a-8347-3142e5ded8cc.html . 2015-01-20.
  84. News: John S. Carroll, acclaimed newspaper editor in Baltimore and L.A., dies at 73. Schudel. Matt. The Washington Post. June 14, 2015. live. https://web.archive.org/web/20160919122215/https://www.washingtonpost.com/national/john-s-carroll-edited-newspapers-in-baltimore-and-los-angeles-dies-at-73/2015/06/14/65bd5c1a-eac7-11e4-9a6a-c1ab95a0600b_story.html. September 19, 2016.
  85. Web site: Barbara Tarbuck, 'General Hospital' and 'American Horror Story' Actress, Dies at 74 . 2016-12-30 . live . https://web.archive.org/web/20161230184246/http://variety.com/2016/tv/news/barbara-tarbuck-dead-dies-general-hospital-jane-jacks-ahs-1201950002/ . 2016-12-30 . 2016-12-30.
  86. Web site: José Baselga, renowned cancer researcher and AstraZeneca oncology R&D head, dies at 61. 21 March 2021. Stat News. statnews.com.
  87. Trout . Jonathan . Roberts . Matthew . Tabet . Michel . Kotkowski . Eithan . Horn . Sarah . 2024-04-09 . Two Hunters from the Same Lodge Afflicted with sporadic CJD: Is Chronic Wasting Disease to Blame? (P7-13.002) . Neurology . en . 102 . 17_supplement_1 . 10.1212/WNL.0000000000204407 . 0028-3878.
  88. August 2010. Detecting Prions in Blood. Microbiology Today. 195. https://web.archive.org/web/20120331021750/https://www.sgm.ac.uk/pubs/micro_today/pdf/081010.pdf. 31 March 2012. 2011-08-21.
  89. Rubenstein R, Chang B, Gray P, Piltch M, Bulgin MS, Sorensen-Melson S, Miller MW . A novel method for preclinical detection of PrPSc in blood . The Journal of General Virology . 91 . Pt 7 . 1883–92 . July 2010 . 20357038 . 10.1099/vir.0.020164-0 . free.
  90. Orrú CD, Bongianni M, Tonoli G, Ferrari S, Hughson AG, Groveman BR, Fiorini M, Pocchiari M, Monaco S, Caughey B, Zanusso G . A test for Creutzfeldt-Jakob disease using nasal brushings . The New England Journal of Medicine . 371 . 6 . 519–29 . August 2014 . 25099576 . 4186748 . 10.1056/NEJMoa1315200.
  91. News: Bone . Ian . Intraventricular Pentosan Polysulphate in Human Prion Diseases: A study of Experience in the United Kingdom . Medical Research Council . 12 July 2006 . 2012-11-09 . live . https://web.archive.org/web/20121103131854/http://www.bbc.co.uk/news/uk-northern-ireland-12667709 . 3 November 2012.
  92. Web site: Use of Pentosan Polysulphate in the treatment of, or prevention of, vCJD . Department of Health:CJD Therapy Advisory Group . 2007-10-30 . live . https://web.archive.org/web/20070705213245/http://www.dh.gov.uk/en/PolicyAndGuidance/HealthAndSocialCareTopics/CJD/CJDGeneralInformation/DH_4031039 . 2007-07-05.
  93. Rainov NG, Tsuboi Y, Krolak-Salmon P, Vighetto A, Doh-Ura K . 12725001 . Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? . . 7 . 5 . 713–26 . May 2007 . 17477808 . 10.1517/14712598.7.5.713.
  94. Web site: The rise and fall of pentosan polysulfate in prion disease . 2022-05-09 . www.cureffi.org.
  95. Pfeifer A, Eigenbrod S, Al-Khadra S, Hofmann A, Mitteregger G, Moser M, Bertsch U, Kretzschmar H . Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice . The Journal of Clinical Investigation . 116 . 12 . 3204–10 . December 2006 . 17143329 . 1679709 . 10.1172/JCI29236.
  96. Web site: Revamp of brain 'could slow CJD' . 2006-12-04 . BBC News . 25 September 2022 . news.bbc.co.uk.
  97. Martin Rossor . Collinge J, Gorham M, Hudson F, Kennedy A, Keogh G, Pal S, Rossor M, Rudge P, Siddique D, Spyer M, Thomas D, Walker S, Webb T, Wroe S, Darbyshire J . Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial . The Lancet. Neurology . 8 . 4 . 334–44 . April 2009 . 19278902 . 2660392 . 10.1016/S1474-4422(09)70049-3.
  98. Karapetyan YE, Sferrazza GF, Zhou M, Ottenberg G, Spicer T, Chase P, Fallahi M, Hodder P, Weissmann C, Lasmézas CI . Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents . Proceedings of the National Academy of Sciences of the United States of America . 110 . 17 . 7044–9 . April 2013 . 23576755 . 3637718 . 10.1073/pnas.1303510110 . 2013PNAS..110.7044K . free.
  99. 10.1016/S1474-4422(22)00082-5. Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldt–Jakob disease: Evaluation of a first-in-human treatment programme. 2022. Mead. Simon. Khalili-Shirazi. Azadeh. Potter. Caroline. Mok. Tzehow. Nihat. Akin. Hyare. Harpreet. Canning. Stephanie. Schmidt. Christian. Campbell. Tracy. Darwent. Lee. Muirhead. Nicola. Ebsworth. Nicolette. Hextall. Patrick. Wakeling. Madeleine. Linehan. Jacqueline. Libri. Vincenzo. Williams. Bryan. Jaunmuktane. Zane. Brandner. Sebastian. Rudge. Peter. Collinge. John. The Lancet Neurology. 21. 4. 342–354. 35305340. 247479825. free.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Creutzfeldt–Jakob disease".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.